Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 14Gastrointestinal 10Thoracic 5Genitourinary 4Breast 2Lymphoid 1Gynecologic 1

Conditions

Hodgkin Disease 1

Interventions

Rituximab 238Cyclophosphamide 192Vincristine 164Doxorubicin 150Prednisone 126Methotrexate 80Cytarabine 79Etoposide 78Dexamethasone 72Radiotherapy 60Bendamustine Hydrochloride 58Mercaptopurine 46Lenalidomide 42pegaspargase 41Prednisolone 38Filgrastim 38ibrutinib 37fludarabine 36Bleomycin 36Daunorubicin 35obinutuzumab 34Asparaginase 33Leucovorin 29venetoclax 28Granulocyte Colony-Stimulating Factor 28Chlorambucil 27Calcium Dobesilate 27Gemcitabine 26Vinblastine 25Thioguanine 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × toripalimab × Lymphoid × Clear all
NCT06170489 2025-02-28

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Recruiting
185 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡